This rarity made Adagen an orphan product—a drug or device that treats a rare disease. Back in 1983, as part of the Orphan Drug Act, the US defined rare diseases as those affecting fewer than ...

Despite these limitations, several first-generation pegylated drugs received regulatory approval. Still in use today are pegademase (Adagen), a pegylated form of the enzyme adenosine deaminase for ...